ArticleVeterinary medicine and science2025
Proliferative Necrotising Otitis Externa in a Cat Treated Successfully With Oclacitinib Maleate With Two Delayed Relapses.
Article in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proliferative Necrotising Otitis Externa in a Cat Treated Successfully With Oclacitinib Maleate With Two Delayed Relapses.Veterinary medicine and science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report documents the successful treatment of a cat with proliferative necrotizing otitis externa (PNOE) using oclacitinib. Novel to this report, two episodes of delayed relapses occurred prior to complete spontaneous resolution, with an apparent dose-dependent response to oclacitinib. Oclacitinib led to complete remission of the initial lesions and those of the first relapse, and the lesions of the second relapse resolved spontaneously. This adds additional evidence to support the use of oclacitinib as an alternative or adjunctive off-label treatment for PNOE, especially in refractory cases. Further studies are needed to assess the safety of long-term use, and to confirm ideal dose rates and treatment duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.